Do you think their plans for these drugs were doomed from the start, or was their execution poor? How might they have made it to market? For antibiotic companies, is it a macro matter of market size and reimbursement rates, or a more manageable business problem of sales/strategy/tactics?
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology